SCHEDULE 1

Article 2

Part I

Controlled Drugs to which section 7(4) of the Misuse of Drugs Act 1971 applies

- 1. The following substances and products, namely:—
 - (a) Bufotenine

Cannabinol

Cannabinol derivatives not being dronabinol or its stereoisomers

Cannabis and cannabis resin

Cathinone

Coca leaf

Concentrate of poppy-straw

Eticyclidine

Etryptamine

Lysergamide

Lysergide and other *N*-alkyl derivatives of lysergamide

Mescaline

Methcathinone

Psilocin

Raw opium

Rolicyclidine

Tenocyclidine

4-Bromo-2,5-dimethoxy-α-methylphenethylamine

N,*N*-Diethyltryptamine

N,*N*-Dimethyltryptamine

2,5-Dimethoxy-α,4-dimethylphenethylamine

N-Hydroxy-tenamphetamine

- 4-Methyl-aminorex;
- (b) any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from tryptamine or from a ring-hydroxy tryptamine by substitution at the nitrogen atom of the sidechain with one or more alkyl substituents but no other substituent;
- (c) the following phenethylamine derivatives, namely:—

Allyl(α -methyl-3,4-methylenedioxyphenethyl)amine

2-Amino-1-(2,5-dimethoxy-4-methylphenyl)ethanol

2-Amino-1-(3,4-dimethoxyphenyl)ethanol

Benzyl(α -methyl-3,4-methylenedioxyphenethyl)amine

4-Bromo-β,2,5-trimethoxyphenethylamine

N-(4-sec-Butylthio-2,5-dimethoxyphenethyl)hydroxylamine

Cyclopropylmethyl(α -methyl-3,4-methylenedioxyphenethyl)amine

- 2-(4,7-Dimethoxy-2,3-dihydro-1*H*-indan-5-yl)ethylamine
- 2-(4,7-Dimethoxy-2,3-dihydro-1*H*-indan-5-yl)-1-methylethylamine
- 2-(2,5-Dimethoxy-4-methylphenyl)cyclopropylamine
- 2-(1,4-Dimethoxy-2-naphthyl)ethylamine
- 2-(1,4-Dimethoxy-2-naphthyl)-1-methylethylamine
- N-(2,5-Dimethoxy-4-propylthiophenethyl)hydroxylamine
- 2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)ethylamine
- 2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)-1-methylethylamine
- α , α -Dimethyl-3,4-methylenedioxyphenethylamine
- α,α -Dimethyl-3,4-methylenedioxyphenethyl(methyl)amine
- Dimethyl(α-methyl-3,4-methylenedioxyphenethyl)amine
- *N*-(4-Ethylthio-2,5-dimethoxyphenethyl)hydroxylamine
- 4-Iodo-2,5-dimethoxy-α-methylphenethyl(dimethyl)amine
- 2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)ethylamine
- 2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)-1-methylethylamine
- 2-(5-Methoxy-2,2-dimethyl-2,3-dihydrobenzo[b]furan-6-yl)-1-methylethylamine
- 2-Methoxyethyl(α -methyl-3,4-methylenedioxyphenethyl)amine
- 2-(5-Methoxy-2-methyl-2,3-dihydrobenzo[b]furan-6-yl)-1-methylethylamine
- β-Methoxy-3,4-methylenedioxyphenethylamine
- 1-(3,4-Methylenedioxybenzyl)butyl(ethyl)amine
- 1-(3,4-Methylenedioxybenzyl)butyl(methyl)amine
- 2-(α-Methyl-3,4-methylenedioxyphenethylamino)ethanol
- α-Methyl-3,4-methylenedioxyphenethyl(prop-2-ynyl)amine
- *N*-Methyl-*N*-(α-methyl-3,4-methylenedioxyphenethyl)hydroxylamine
- O-Methyl-N-(α-methyl-3,4-methylenedioxyphenethyl)hydroxylamine
- α-Methyl-4-(methylthio)phenethylamine
- β,3,4,5-Tetramethoxyphenethylamine
- β,2,5-Trimethoxy-4-methylphenethylamine;
- (d) any compound (not being methoxyphenamine or a compound for the time being specified in sub-paragraph (a) above) structurally derived from phenethylamine, an *N*-alkylphenethylamine, α-methylphenethylamine, an *N*-alkyl-α-methylphenethylamine, α-ethylphenethylamine, or an *N*-alkyl-α-ethylphenethylamine by substitution in the ring to any extent with alkyl, alkoxy, alkylenedioxy or halide substitutents, whether or not further substituted in the ring by one or more other univalent substituents;
- (e) any compound (not being a compound for the time being specified in Part II of this Schedule) structurally derived from fentanyl by modification in any of the following ways, that is to say—
 - (i) by replacement of the phenyl portion of the phenethyl group by any heteromonocycle whether or not further substituted in the heterocycle;
 - (ii) by substitution in the phenethyl group with alkyl, alkenyl, alkoxy, hydroxy, halogeno, haloalkyl, amino or nitro groups;

- (iii) by substitution in the piperidine ring with alkyl or alkenyl groups;
- (iv) by substitution in the aniline ring with alkyl, alkoxy, alkylenedioxy, halogeno or haloalkyl groups;
- (v) by substitution at the 4-position of the piperidine ring with any alkoxycarbonyl or alkoxyalkyl or acyloxy group;
- (vi) by replacement of the N-propionyl group by another acyl group;
- (f) any compound (not being a compound for the time being specified in Part II of this Schedule) structurally derived from pethidine by modification in any of the following ways, that is to say—
 - (i) by replacement of the 1-methyl group by an acyl, alkyl whether or not unsaturated, benzyl or phenethyl group, whether or not further substituted;
 - (ii) by substitution in the piperidine ring with alkyl or alkenyl groups or with a propano bridge, whether or not further substituted;
 - (iii) by substitution in the 4-phenyl ring with alkyl, alkoxy, aryloxy, halogeno or haloalkyl groups;
 - (iv) by replacement of the 4-ethoxycarbonyl by any other alkoxycarbonyl or any alkoxyalkyl or acyloxy group;
 - (v) by formation of an N-oxide or of a quaternary base.
- 2. Any stereoisomeric form of a substance specified in paragraph 1 above.
- 3. Any ester or ether of a substance specified in paragraph 1 or 2 above.
- 4. Any salt of a substance specified in any of paragraphs 1 to 3 above.
- 5. Any preparation or other product containing a substance or product specified in any of paragraphs 1 to 4 above.

Part II

Controlled Drugs excepted from Part I

1. The compounds referred to in paragraph 1(e) of Part I of this Schedule are—

Alfentanil

Carfentanil

Lofentanil

Sufentanil

2. The compounds referred to in paragraph 1(f) of Part I of this Schedule are—

Allylprodine

Alphameprodine

Alphaprodine

Anileridine

Betameprodine

Betaprodine

Hydroxypethidine

Properidine

Document Generated: 2023-06-05

Status: This is the original version (as it was originally made). This item of legislation is currently only available in its original format.

Trimeperidine